{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:48:02Z","timestamp":1791312482380,"version":"4.3.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s13555-024-01165-5","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T05:05:17Z","timestamp":1715835917000},"page":"1531-1546","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Patient Burden of Nonsegmental Vitiligo: A US Real-World Survey of Dermatologists and Their Patients"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2786-0708","authenticated-orcid":false,"given":"David","family":"Rosmarin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1015-3823","authenticated-orcid":false,"given":"Jennifer H.","family":"Lofland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0380-0372","authenticated-orcid":false,"given":"Simran","family":"Marwaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7015-1021","authenticated-orcid":false,"given":"James","family":"Piercy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2171-8228","authenticated-orcid":false,"given":"Peter","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6042-5476","authenticated-orcid":false,"given":"Jinan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,16]]},"reference":[{"issue":"1","key":"1165_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2016.10.048","volume":"77","author":"M Rodrigues","year":"2017","unstructured":"Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE, Vitiligo Working Group. New discoveries in the pathogenesis and classification of vitiligo. J Am Acad Dermatol. 2017;77(1):1\u201313.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1165_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/jamadermatol.2021.4724","volume":"158","author":"K Gandhi","year":"2022","unstructured":"Gandhi K, Ezzedine K, Anastassopoulos KP, et al. Prevalence of vitiligo among adults in the United States. JAMA Dermatol. 2022;158(1):43\u201350.","journal-title":"JAMA Dermatol"},{"issue":"10","key":"1165_CR3","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1111\/j.1365-4632.2011.05377.x","volume":"51","author":"C Kr\u00fcger","year":"2012","unstructured":"Kr\u00fcger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children\/adolescents and adults. Int J Dermatol. 2012;51(10):1206\u201312.","journal-title":"Int J Dermatol"},{"issue":"5","key":"1165_CR4","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1093\/bjd\/ljad245","volume":"189","author":"IH Hamzavi","year":"2023","unstructured":"Hamzavi IH, Bibeau K, Grimes P, et al. Exploring the natural and treatment history of vitiligo: perceptions of patients and healthcare professionals from the global VALIANT study. Br J Dermatol. 2023;189(5):569\u201377.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1165_CR5","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1159\/000506103","volume":"236","author":"C Bergqvist","year":"2020","unstructured":"Bergqvist C, Ezzedine K. Vitiligo: a review. Dermatology. 2020;236(6):571\u201392.","journal-title":"Dermatology"},{"issue":"2","key":"1165_CR6","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/S0190-9622(86)70160-6","volume":"15","author":"JR Porter","year":"1986","unstructured":"Porter JR, Beuf AH, Lerner A, Nordlund J. Psychosocial effect of vitiligo: a comparison of vitiligo patients with \u201cnormal\u201d control subjects, with psoriasis patients, and with patients with other pigmentary disorders. J Am Acad Dermatol. 1986;15(2):220\u20134.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1165_CR7","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2340\/00015555-1981","volume":"95","author":"C Kr\u00fcger","year":"2015","unstructured":"Kr\u00fcger C, Schallreuter KU. Stigmatisation, avoidance behaviour and difficulties in coping are common among adult patients with vitiligo. Acta Derm Venereol. 2015;95(5):553\u20138.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"1165_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1468-3083.2005.01369.x","volume":"20","author":"K Ongenae","year":"2006","unstructured":"Ongenae K, Beelaert L, van Geel N, Naeyaert JM. Psychosocial effects of vitiligo. J Eur Acad Dermatol Venereol. 2006;20(1):1\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1165_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12955-020-1278-7","volume":"18","author":"N Hamidizadeh","year":"2020","unstructured":"Hamidizadeh N, Ranjbar S, Ghanizadeh A, Parvizi MM, Jafari P, Handjani F. Evaluating prevalence of depression, anxiety and hopelessness in patients with vitiligo on an Iranian population. Health Qual Life Outcomes. 2020;18(1):20.","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"1165_CR10","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/bjd.16049","volume":"178","author":"O Osinubi","year":"2018","unstructured":"Osinubi O, Grainge MJ, Hong L, et al. The prevalence of psychological comorbidity in people with vitiligo: a systematic review and meta-analysis. Br J Dermatol. 2018;178(4):863\u201378.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1165_CR11","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1111\/bjd.15199","volume":"177","author":"Y Lai","year":"2017","unstructured":"Lai Y, Yew Y, Kennedy C, Schwartz R. Vitiligo and depression: a systematic review and meta-analysis of observational studies. Br J Dermatol. 2017;177(3):708\u201318.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1165_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13418","volume":"33","author":"RE Simons","year":"2020","unstructured":"Simons RE, Zevy DL, Jafferany M. Psychodermatology of vitiligo: psychological impact and consequences. Dermatol Ther. 2020;33(3): e13418.","journal-title":"Dermatol Ther"},{"issue":"3","key":"1165_CR13","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.jaad.2023.04.052","volume":"89","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Simpson B, Abuabara K, et al. Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand: a cross sectional study from the TARGET-DERM AD cohort. J Am Acad Dermatol. 2023;89(3):519\u201328.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1165_CR14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s13555-021-00635-4","volume":"12","author":"M Lebwohl","year":"2022","unstructured":"Lebwohl M, Langley RG, Paul C, et al. Evolution of patient perceptions of psoriatic disease: results from the understanding psoriatic disease leveraging insights for treatment (UPLIFT) survey. Dermatol Ther (Heidelb). 2022;12(1):61\u201378.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"1165_CR15","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/jdv.16927","volume":"35","author":"V Narayan","year":"2021","unstructured":"Narayan V, Uitentuis S, Luiten R, Bekkenk M, Wolkerstorfer A. Patients\u2019 perspective on current treatments and demand for novel treatments in vitiligo. J Eur Acad Dermatol Venereol. 2021;35(3):744\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1165_CR16","unstructured":"Opzelura\u2122 (ruxolitinib cream). Full prescribing information. Incyte Corporation, Wilmington; 2023."},{"issue":"1","key":"1165_CR17","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jaad.2022.12.029","volume":"89","author":"R Sidbury","year":"2023","unstructured":"Sidbury R, Alikhan A, Bercovitch L, et al. Guidelines of care for the management of atopic dermatitis in adults with topical therapies. J Am Acad Dermatol. 2023;89(1):e1\u201320.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1165_CR18","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: Disease-Specific Programmes\u2013a means to understand. Curr Med Res Opin. 2008;24(11):3063\u201372.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"1165_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010352","volume":"6","author":"SM Babineaux","year":"2016","unstructured":"Babineaux SM, Curtis B, Holbrook T, Milligan G, Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme. BMJ Open. 2016;6(8): e010352.","journal-title":"BMJ Open"},{"key":"1165_CR20","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2147\/DMSO.S120101","volume":"9","author":"V Higgins","year":"2016","unstructured":"Higgins V, Piercy J, Roughley A, et al. Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes. 2016;9:371\u201380.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"1165_CR21","unstructured":"US Department of Health and Human Services. Summary of the HIPAA Privacy Rule. 2003 [cited 2023 June 19]; http:\/\/www.hhs.gov\/sites\/default\/files\/privacysummary.pdf"},{"key":"1165_CR22","unstructured":"Health Information Technology (HITECH). Health Information Technology Act. 2009 [cited 2023 June 19]; https:\/\/www.healthit.gov\/sites\/default\/files\/hitech_act_excerpt_from_arra_with_index.pdf"},{"issue":"5","key":"1165_CR23","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353\u201365.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"1165_CR24","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361\u201370.","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"1165_CR25","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1016\/j.jaad.2012.01.038","volume":"69","author":"E Lilly","year":"2013","unstructured":"Lilly E, Lu PD, Borovicka JH, et al. Development and validation of a vitiligo-specific quality-of-life instrument (VitiQoL). J Am Acad Dermatol. 2013;69(1):e11\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"1165_CR26","unstructured":"StataCorp. Stata Statistical Software: Release 16. College Station: StataCorp LLC 2019."},{"issue":"9","key":"1165_CR27","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/jdv.18129","volume":"36","author":"M Picardo","year":"2022","unstructured":"Picardo M, Huggins RH, Jones H, Marino R, Ogunsola M, Seneschal J. The humanistic burden of vitiligo: a systematic literature review of quality-of-life outcomes. J Eur Acad Dermatol Venereol. 2022;36(9):1507\u201323.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1165_CR28","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/bjd.20596","volume":"186","author":"V Eleftheriadou","year":"2022","unstructured":"Eleftheriadou V, Atkar R, Batchelor J, et al. British Association of Dermatologists guidelines for the management of people with vitiligo 2021. Br J Dermatol. 2022;186(1):18\u201329.","journal-title":"Br J Dermatol"},{"key":"1165_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.986918","author":"Y Feng","year":"2022","unstructured":"Feng Y, Lu Y. Advances in vitiligo: update on therapeutic targets. Front Immunol. 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.986918.","journal-title":"Front Immunol"},{"issue":"10244","key":"1165_CR30","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S0140-6736(20)30609-7","volume":"396","author":"D Rosmarin","year":"2020","unstructured":"Rosmarin D, Pandya AG, Lebwohl M, et al. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. Lancet. 2020;396(10244):110\u201320.","journal-title":"Lancet"},{"issue":"4","key":"1165_CR31","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/j.1365-2133.2012.11056.x","volume":"167","author":"V Eleftheriadou","year":"2012","unstructured":"Eleftheriadou V, Thomas K, Whitton M, Batchelor J, Ravenscroft J. Which outcomes should we measure in vitiligo? Results of a systematic review and a survey among patients and clinicians on outcomes in vitiligo trials. Br J Dermatol. 2012;167(4):804\u201314.","journal-title":"Br J Dermatol"},{"issue":"9988","key":"1165_CR32","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","volume":"386","author":"K Ezzedine","year":"2015","unstructured":"Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74\u201384.","journal-title":"Lancet"},{"issue":"2","key":"1165_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/etm.2021.10229","volume":"22","author":"DE Kubelis-L\u00f3pez","year":"2021","unstructured":"Kubelis-L\u00f3pez DE, Zapata-Salazar NA, Said-Fern\u00e1ndez SL, et al. Updates and new medical treatments for vitiligo. Exp Ther Med. 2021;22(2):1\u201311.","journal-title":"Exp Ther Med"},{"issue":"6","key":"1165_CR34","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1111\/pcmr.12878","volume":"33","author":"ZA Abdel-Malek","year":"2020","unstructured":"Abdel-Malek ZA, Jordan C, Ho T, Upadhyay PR, Fleischer A, Hamzavi I. The enigma and challenges of vitiligo pathophysiology and treatment. Pigment Cell Melanoma Res. 2020;33(6):778\u201387.","journal-title":"Pigment Cell Melanoma Res"},{"key":"1165_CR35","doi-asserted-by":"crossref","unstructured":"Huggins RH, Gardner J, Pandya AG. Patient support, education, and compliance. In: Gupta S, Olsson MJ, Parsad D, Lim HW, van Geel N, Pandya AG, eds. Vitiligo: medical and surgical management. Wiley; 2018. pp. 69\u201375.","DOI":"10.1002\/9781118937303.ch9"},{"issue":"3","key":"1165_CR36","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.jaad.2016.09.034","volume":"76","author":"N van Geel","year":"2017","unstructured":"van Geel N, Lommerts JE, Bekkenk MW, et al. Development and validation of a patient-reported outcome measure in vitiligo: the Self Assessment Vitiligo Extent Score (SA-VES). J Am Acad Dermatol. 2017;76(3):464\u201371.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1165_CR37","first-page":"504","volume":"99","author":"A Maamri","year":"2021","unstructured":"Maamri A, Badri T. Sexual disorders in patients with vitiligo. Tunis Med. 2021;99(5):504.","journal-title":"Tunis Med"},{"issue":"3","key":"1165_CR38","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1080\/0092623X.2015.1010678","volume":"42","author":"D Sarhan","year":"2016","unstructured":"Sarhan D, Mohammed GF, Gomaa AH, Eyada MM. Female genital dialogues: female genital self-image, sexual dysfunction, and quality of life in patients with vitiligo with and without genital affection. J Sex Marital Ther. 2016;42(3):267\u201376.","journal-title":"J Sex Marital Ther"},{"issue":"9","key":"1165_CR39","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1001\/archfami.9.9.876","volume":"9","author":"M Olfson","year":"2000","unstructured":"Olfson M, Shea S, Feder A, et al. Prevalence of anxiety, depression, and substance use disorders in an urban general medicine practice. Arch Fam Med. 2000;9(9):876\u201383.","journal-title":"Arch Fam Med"},{"issue":"4","key":"1165_CR40","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1080\/13696998.2019.1572015","volume":"22","author":"N Li","year":"2019","unstructured":"Li N, Chan E, Peterson S. The economic burden of depression among adults with rheumatoid arthritis in the United States. J Med Econ. 2019;22(4):372\u20138.","journal-title":"J Med Econ"},{"key":"1165_CR41","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s41927-019-0092-5","volume":"3","author":"S Peterson","year":"2019","unstructured":"Peterson S, Piercy J, Blackburn S, Sullivan E, Karyekar CS, Li N. The multifaceted impact of anxiety and depression on patients with rheumatoid arthritis. BMC Rheumatol. 2019;3:43.","journal-title":"BMC Rheumatol"},{"key":"1165_CR42","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s41927-017-0003-6","volume":"1","author":"R Sruamsiri","year":"2017","unstructured":"Sruamsiri R, Kaneko Y, Mahlich J. The underrated prevalence of depression in Japanese patients with rheumatoid arthritis\u2014evidence from a Nationwide survey in Japan. BMC Rheumatol. 2017;1:5.","journal-title":"BMC Rheumatol"},{"issue":"10","key":"1165_CR43","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1111\/jdv.18257","volume":"36","author":"K Bibeau","year":"2022","unstructured":"Bibeau K, Pandya A, Ezzedine K, et al. Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA. J Eur Acad Dermatol Venereol. 2022;36(10):1831\u201344.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1165_CR44","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ijwd.2017.11.005","volume":"4","author":"P Grimes","year":"2018","unstructured":"Grimes P, Miller M. Vitiligo: patient stories, self-esteem, and the psychological burden of disease. Int J Womens Dermatol. 2018;4(1):32\u20137.","journal-title":"Int J Womens Dermatol"},{"issue":"10","key":"1165_CR45","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamadermatol.2023.2787","volume":"159","author":"K Bibeau","year":"2023","unstructured":"Bibeau K, Ezzedine K, Harris JE, et al. Mental health and psychosocial quality-of-life burden among patients with vitiligo: findings from the global VALIANT study. JAMA Dermatol. 2023;159(10):1124\u20138.","journal-title":"JAMA Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01165-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01165-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01165-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T09:03:58Z","timestamp":1718183038000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01165-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,16]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1165"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01165-5","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,16]]},"assertion":[{"value":"8 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"David Rosmarin has received honoraria as a consultant for AbbVie, Abcuro, AltruBio, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Concert, Dermavant Sciences, Dermira, Incyte Corporation, Janssen, Kyowa Kirin, Lilly, Novartis, Pfizer, Regeneron Pharmaceuticals, Revolo Biotherapeutics, Sanofi, Sun Pharmaceuticals, UCB, and Viela Bio; has received research support from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Dermira, Galderma, Incyte Corporation, Janssen, Lilly, Merck, Novartis, Pfizer, and Regeneron Pharmaceuticals; and has served as a paid speaker for AbbVie, Amgen, Celgene, Janssen, Lilly, Novartis, Pfizer, Regeneron Pharmaceuticals, and Sanofi. Jennifer H. Lofland and Jinan Liu are employees and stockholders of Incyte Corporation. Simran Marwaha, James Piercy, and Peter Anderson are employees of Adelphi Group, which was contracted by Incyte Corporation to perform this analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The Adelphi Vitiligo Disease Specific Programme\u2122 received ethics exemption from the Pearl Institutional Review Board (study protocol number #21-ADRW-122) based on the use of aggregated and de-identified patient data. All data were collected in such a way that patients and dermatologists could not be identified directly; all data were aggregated and de-identified before receipt. Each survey was performed in full accordance with relevant legislation at the time of data collection, including the US Health Insurance Portability and Accountability Act of 1996 and Health Information Technology for Economic and Clinical Health Act legislation. Both physicians and patients consented to take part in the research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}